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Fig 2. Ultrasound (U/S) velocity ratio progression over time.
Table. Relationship of duplex and computed tomography (CT) scan
ﬁndings and graft failure
Graft status
P valueFailed, No. (%) Patent, No. (%)
U/S velocity ratio
<2.0 3 (0.5) 622 (99.5) <.001a
2.0-3.5 3 (12) 22 (88)
>3.5 4 (67) 2 (33)
CT stenosis
0-49% 0 (0) 578 (100) <.001a
50-59% 2 (5) 35 (95)
60-69% 5 (22) 18 (78)
70-79% 2 (14) 12 (86)
>80% 1 (25) 3 (75)
U/S, Ultrasound.
aFisher’s exact test.
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U/S velocity ratios >3.5 are strongly correlated with graft failure and also
that low and even moderate CT stenosis correlate with graft success. We
show that a moderately elevated U/S velocity ratio in the 2 to 3.5 range
is largely clinically benign, with few of these grafts ultimately failing and
that velocity ratios for this group tend to improve with time. This is a
step toward deﬁning the relationship between imaging and outcome for
vein grafts, an understanding of which will likely contribute to the establish-
ment of the optimal strategy for graft monitoring.
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Introduction: Limited single-center experiences with the treatment
of infected endovascular endografts (I-EVAR) have been reported. We per-
formed a multicenter review of the surgical care of these patients to eluci-
date short-term and long-term outcomes.
Methods: A retrospective analysis of all EVAR explants from 2000 to
2014 at four institutionswas performed. Patients with I-EVAR undergoing sur-
gical treatmentwere reviewed.Datawereobtaineddetailingpreoperative patient
demographics, postoperativemorbidity andmortality, and long-term follow-up.
Results: Thirty-six patients, 30 male (83%) and six female (17%), with a
median age of 69 years (range, 54-80 years), were treated with endovascular
graft excision and revascularization for I-EVAR. Average time from initial
EVAR to explantation was 589 days (range, 43-2466 days). Preoperativecomorbidities include hypertension, 32 (89%); tobacco use, 31 (86%); coro-
nary artery disease, 26 (72%); hyperlipidemia, 25 (69%); peripheral arterial dis-
ease, 13 (36%); cerebrovascular disease, 10 (28%); diabetes, 10 (28%); chronic
obstructive pulmonary disease, 9 (25%); and chronic kidney disease, 9 (25%).
The most common presenting symptoms were leukocytosis in 23 (63%), pain
in 21 (58%), and fever in 20 (56%), which were present an average of 22 days
prior to explantation. Eight different types of endograft were removed. Three
patients (8%) underwent emergency explantation. Thirty-two patients under-
went total graft excision (89%), and four patients underwent partial excision
(11%). Methods of reconstruction included in situ reconstruction in 25
(69%) and extra-anatomic reconstruction in 11 (31%). Conduits used in
reconstruction consisted of Dacron, with or without rifampin treatment, poly-
tetraﬂuoroethylene, cryopreserved allograft, and superﬁcial femoral vein.
Forty-nine organisms grew from operative cultures. Gram-positive organisms
were the most common isolate found in 32 (88%), including Staphylococcus in
12 (33%), and Streptococcus in six (17%). Anaerobic organisms were cultured
in 11 patients (31%), gram-negative organisms in 8 (22%), and fungus in 5
(14%). Amajority of patients (21 [58%]) were treated with long-term suppres-
sive antibiotic therapy. Early complications included acute renal failure in 12
(33%), respiratory failure requiring tracheostomy in 3 (8%), bleeding in 2
(6%), and sepsis in 2 (6%). Six patients required reexploration due to hema-
toma, infected hematoma, lymphatic leak, small-bowel perforation, open
abdomen at initial operation, and anastomotic bleeding. Perioperative mortal-
ity was 8% (3 of 36) and overall mortality was 25% (9 of 36) at a mean follow-
up of 402 days (range, 0-2472 days). Type of reconstruction (in situ vs extra-
anatomic) or conduit type did not affect perioperative or overall mortality.
Conclusions: I-EVAR is a rare but potentially devastating clinical
problem. Although perioperative mortality is acceptable, overall mortality
is high. The most common postoperative complication was acute renal fail-
ure; therefore, aortic cross-clamp time should be minimized. Although this
is the largest series of I-EVAR, further studies will be necessary to under-
stand risk factors and preventive measures.
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Introduction: The AORFIX endograft (Lombard Medical) is a highly
conformablemodular nitinol/polyester device designed for infrarenal or trans-
renal ﬁxation. PYTHAGORAS is the ﬁrst clinical trial to evaluate outcomes for
EVAR using AORFIX in highly angulated infrarenal aortic necks ($60).
Methods: PYTHAGORAS is a prospective nonrandomized clinical
trial that enrolled and treated 151 patients with neck angles $60 (high-an-
gle) and 67 patients with neck angles <60 (low-angle) in the EVAR group.
The primary control group was patients concurrently undergoing open repair
(n ¼ 76), and a meta-analysis of 323 patients from U.S. EVAR clinical trials
(Society for Vascular Surgery Lifeline) served as the secondary control. We
compared the high- and low-angle EVAR groups with the open group in
PYTHAGORAS in terms of mortality (30-day and 1-year) and freedom
from major adverse events (MAEs) deﬁned by the Society for Vascular Sur-
gery (myocardial infarction, cerebrovascular accident, renal failure, respira-
tory failure, paralysis/paraparesis, bowel ischemia, death, and bleeding)
using the Fisher exact test (Table I). Graft migration and type I and III endo-
leak were compared between high-angle and low-angle groups (Table II).
Results: Patient demographics and comorbidities were similar be-
tween the EVAR and open group with the exception of age (EVAR 76 6
8 vs open 70 6 7 years; P < .05), congestive heart failure (EVAR 13% vs
open 7% P ¼ .015), neck angle (EVAR all 71 6 23 and high angle 83
6 15 vs open 48 6 23; P < .05), and female gender (EVAR high angle
35% vs open 17%; P < .0001). Sac diameter and other anatomic variables
were similar. Operative data favored the EVAR group for procedure dura-
tion, blood loss, and hospital length of stay (all P < .05). There was no
statistically signiﬁcant difference between freedom from MAEs, 30-day,
and 1-year mortality between of low-angle or high-angle EVAR groups
compared with the PYTHAGOAS open control group (Table I). Also, there
was no difference between low-angle and high-angle patients in regards to
sac shrinkage, type I/III endoleak, and endograft migration (Table II).
Conclusions: PYTHAGORAS is the ﬁrst U.S. clinical trial designed
to evaluate the performance of EVAR in a population of patients with
neck angles $60. Despite signiﬁcant predictors of worse short-term and
long-term outcomes (female gender, congestive heart failure, neck angle),
MAEs and other pertinent outcomes were better or similar to open repair
Table I. Mortality and freedom from major adverse events (MAEs) comparison between AORFIX and Pythagoras open control group
Outcome
Aorﬁx<60
(n ¼ 67), %
Aorﬁx 60-133
(n ¼ 151), %
PYTHAGORAS
open, %
SVS control group
(n ¼ 323), %
P value Aorﬁx vs open control
<60 >60
Freedom from SVS
MAE, 30 days
92.5 81.5 57.9 56.3 <.001 <.001
Mortality
30 days 1.5 2.0 1.3 2.8 .928 .717
1 year 3.0 7.3 6.6 6.5 .320 .845
SVS, Society for Vascular Surgery.
Table II. Sac shrinkage, endoleaks, and migration comparison between
low and high angle abdominal aortic aneurysm treated with AORFIX
Variable
Aorﬁx
<60, %
Aorﬁx
>60, % P value
Outcome at 1 year
Sac shrinkage (5 mm) 36.7 44.1 .7335
Sac expansion (5 mm) 0 1.8 1.000
Type I/III leak 0 1.9 1.000
Migration (10 mm) 0 1.9 1.000
Table. Patient mortality from 2005 to 2011
Operative
year
No mortality,
No. (%)
Death #24 hours
after surgery, No. (%)
Death >24 hours
after surgery, No. (%)
2005 38 (70.4) 8 (14.8) 8 (14.8)
2006 127 (65.1) 34 (17.4) 34 (17.4)
2007 260 (71.4) 36 (9.9) 68 (18.7)
2008 343 (68.1) 64 (12.7) 97 (19.2)
2009 359 (71.7) 57 (11.4) 85 (17.0)
2010 402 (73.2) 59 (10.7) 88 (16.0)
2011 452 (76.1) 63 (10.6) 79 (13.3)
Chi-squared test statistic for Pearson’s correlation coefﬁcient of trend:
P ¼ .002.
JOURNAL OF VASCULAR SURGERY
1718 Abstracts December 2014and similar to trials with less severe anatomy. The results encourage the use
of AORFIX in patients with highly angulated neck anatomy who may other-
wise have no endovascular option.
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Introduction: Emergency abdominal aortic aneurysm (AAA) repair
carries a high risk of morbidity and mortality. This study seeks to examine
morbidity and mortality trends from the National Surgical Quality Improve-
ment Program (NSQIP) database, and identify potential risk factors.Fig. Patient mortality from 2005 to 2011 (daMethods: All emergency AAA repairs were identiﬁed using the
NSQIP database from 2005-2011. Univariate analysis (using Student’s t-
test, Chi-squared, and Fisher’s exact test) and multivariate logistic regres-
sion was performed to examine trends in mortality and morbidity.
Results: Out of 2761 patients who underwent emergency AAA
repair, 321 (11.6%) died within 24 hours of surgery. Of the remaining
2440 patients, 1133 (46.4%) had major complications and 459 (18.8%)
died during the postoperative period. From 2005 to 2011, there was a sig-
niﬁcant decrease in patient mortality, particularly in patients who survived
the perioperative period (P ¼ .002; Fig; Table). Total complications
increased overall (P < .0001); however, major complications decreased
from 58.7% in 2005 to 42.6% in 2011 (P < .0001) in the patients who sur-
vived beyond 24 hours. The use of endovascular repair increased over the
study period (P < .0001). On multivariate analysis of patients who survived
past the initial 24-hour period, age (odds ratio [OR], 1.050), open repair
(OR, 1.8), and presence of a major complication (OR, 3.3) were signiﬁ-
cantly associated with death (P < .001).ta labels represent percentage mortality).
